ChristopherGeorgeKanakryMD

Oncology • Baltimore, MD

Physician

Join to view full profile

Dr. Kanakry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kanakry's full profile

Already have an account?

Office
Johns Hopkins Hospital
600 N Wolfe Street
Baltimore, MD 21287
Phone+1 410-955-5000

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
Duke University School of MedicineClass of 2007

Certifications & Licensure

MD State Medical License 2010 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Start of enrollment: 2021 Sep 23
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies Start of enrollment: 2022 May 23
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Optimizing PTCy Dose and Timing Start of enrollment: 2019 Jul 09
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation Start of enrollment: 2022 Nov 18
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Genetic testing to identify hereditary predispositions to haematological malignancy is critical prior to allogenic haematopoietic cell transplant.
Amra Kajdic, Natalie T Deuitch, Erica Bresciani, Joie Davis, Kathleen Craft
British Journal of Haematology. 2025-01-26
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gra...
Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail
Transplantation and Cellular Therapy. 2025-01-02
F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation.
Jennifer Holter-Chakrabarty, Lacey McNally, John Levine, James Ferrara, Sara K Vesely
Radiology. Imaging Cancer. 2025-01-01

Abstracts/Posters

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Christopher G. Kanakry, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 8th, 2014
How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13th, 2013